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Abstract
Background: Treating patients with hepatocellular carcinoma (HCC) remains a challenge, especially
when the disease presents at an advanced stage. The aim of this retrospective study was to determine
the efficacy of liver resection in patients who fulfil or exceed University of California San Francisco (UCSF)
criteria by assessing longterm outcome.
Methods: Between 2002 and 2008, 59 patients with large HCC (>5 cm) underwent hepatectomy.
Thirty-two of these patients fulfilled UCSF criteria for transplantation (group A) and 27 did not (group B).
Disease-free survival and overall survival rates were compared between the two groups after resection
and were critically evaluated with regard to patient eligibility for transplant.
Results: In all patients major or extended hepatectomies were performed. There was no perioperative
mortality. Morbidity consisted of biliary fistula, abscess, pleural effusion and pneumonia and was signifi-
cantly higher in patient group B. Disease-free survival rates at 1, 3 and 5 years were 66%, 37% and 34%
in group A and 56%, 29% and 26% in group B, respectively (P < 0.01). Survival rates at 1, 3 and 5 years
were 73%, 39% and 35% in group A and 64%, 35% and 29% in group B, respectively (P = 0.04). The
recurrence rate was higher in group B (P = 0.002).
Conclusions: Surgical resection, if feasible, is suggested in patients with large HCC and can be
performed with acceptable overall and disease-free survival and morbidity rates. In patients eligible for
transplantation, resection may also have a place in the management strategy when waiting list time is
prolonged for reasons of organ shortage or when the candidate has low priority as a result of a low MELD
(model for end-stage liver disease) score.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignancies worldwide. The rate of HCC occurrence increased
from 1.4 per 100 000 in 1980 to 2.4 per 100 000 in 1991–1995.1 An
aetiological association between hepatitis B virus (HBV) infection
and the development of HCC has been established and HBV-
infected subjects have a relative risk for HCC 200 times greater
than that of non-infected individuals.2 Hepatitis C virus is also
proving an important predisposing factor for this malignancy,
with incidence rates of 7% at 5 years and 14% at 10 years.2 The
prognosis depends on tumour stage and degree of liver function,
which affects the tolerance to invasive treatments. Despite recent
advances in diagnostic imaging, HCC frequently presents at an
advanced stage as a result of the absence of early symptoms and
poorly performed screening.3
The use of conventional Milan criteria (single HCC of <5 cm or
up to three nodules of <3 cm), has led to careful patient selection,
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resulting in improved outcomes in liver transplantation (LT) in
patients with HCC over the last 10 years.4 The growing experience
in and success of LT in the treatment of HCC have raised contro-
versies related to the expansion of the Milan criteria.
Among the proposed expanded criteria, the University of
California San Francisco (UCSF) criteria (single tumour nodule
6.5 cm, or three or fewer tumours of which the largest is
4.5 cm and the sum of the tumour diameters is 8 cm) reflect
a modest expansion of tumour size limits.5 The major drawback
to LT is the scarcity of donors. Increases in waiting time have
resulted in 20% of potential candidates dropping out because
outcome on an intention-to-treat basis is jeopardized by the
progression of disease.6
Liver transplantation is the treatment of choice for patients
with early HCC and moderate to severe cirrhosis.4 By contrast,
the optimal treatment for patients with early HCC and preserved
liver function seems to be liver resection (LR).7,8 In this situation
transplantation should be considered in cases of unfavourable
histological findings,9,10 or early-stage recurrence of HCC.11 The
treatment of patients with HCC beyond the Milan criteria is more
challenging because no firm guidelines exist; a more individual-
ized multimodal strategy consisting of LR, salvage LT and primary
LT should be considered.12
The aim of this retrospective study was to determine the
efficacy of LR, in terms of longterm and disease-free survival,
in patients who do and do not fulfil UCSF criteria.
Materials and methods
Between October 2002 and November 2008, a total of 357 patients
with HCC were admitted to the Liver and Pancreatic Surgical Unit
at Agia Olga, Konstantopouleio Hospital, Athens. Curative liver
resection was performed in 59 cirrhotic patients presenting with
large HCC, which was defined as a tumour with diameter 5 cm
in the pathology report. Cirrhosis was microscopically confirmed
in all resected specimens. Non-tumorous liver was analysed using
the fibrosis classification scheme proposed by Ishak et al.13
Based on findings from the pathology report, patients were
divided into two groups and data regarding longterm outcome
were analysed retrospectively. Group A consisted of those patients
who fulfilled UCSF criteria and group B consisted of patients who
exceeded UCSF criteria.
Liver function was evaluated by Child–Turcotte–Pugh classifi-
cation, liver biochemistry and MELD (model for end-stage liver
disease) score.
Platelet count was >90 000/ml in all patients.
Portal hypertension was defined by the presence of varices,
a platelet count of <100 000/ml or indirect echographic markers
(ascites, portal vein diameter 13 mm, spleen length >15 cm,
maximal and mean velocimetry of portal vein flow [<20 cm/s and
<12 cm/s, respectively]). Ascites, encephalopathy, abnormal bili-
rubin level (>2 mg/dl), previous history of variceal bleeding and
portal hypertension were contraindications for liver resection.
Hepatocellular carcinoma was diagnosed on the basis of stan-
dard clinical and imaging criteria, a-fetoprotein levels (AFP) and
biopsy. Routine biopsies were not performed on tumorous or
non-tumorous liver tissue.
Preoperative tumour stage was based on two abdominal
imaging studies, such as ultrasonography, computed tomo-
graphy (CT) or magnetic resonance imaging (MRI). Extrahepatic
metastasis was excluded before LR based on chest and abdominal
CT or MRI. Tumour contraindications for LR were presence of
extrahepatic disease or macroscopic vascular invasion. Patients
with diffuse infiltrating HCC were excluded, as were patients with
regional lymph node involvement discovered at surgery (stage
IV B; Table 1). Liver resection was performed in all patients. When
the estimated future liver remnant (FLR) was expected to be
< 40% of the total liver volume (TLV) as calculated by three-
dimensional CT volumetry, portal vein embolization (PVE) was
performed 6–8 weeks before LR to induce hypertrophy of the FLR.
CT volumetry was estimated prior to and after PVE for accurate
assessment of the functional residual liver volume and occasion-
ally in patients who did not undergo PVE.
Hepatic resection was defined as major if three or more seg-
ments were resected and minor if fewer than three segments were
resected. Hepatic resection was defined as extended when three
liver sectors were resected (trisectorectomy): more than four seg-
ments on the right side and more than three segments on the left
side. Segment I was included or not in accordance with tumour
expansion.
Table 1 Staging classification for hepatocellular carcinoma based on
American Liver Tumor Study Group criteria
Modified tumour–node–metastasis (TNM) staging
classification
T0 Tumour not found
T1 One nodule < 1.9 cm
T2 One nodule 2.0–5.0 cm
Two or three nodules, all < 3.0 cm
T3 One nodule > 5.0 cm
Two or three nodules, at least one > 3.0 cm
T4a Four or more nodules
T4b One or more nodules plus gross intrahepatic portal
or hepatic vein involvement, as indicated by CT,
MRI or ultrasound
N1 Any regional (porta hepatis) nodes involved
M1 Any metastatic disease, including extrahepatic portal
or hepatic vein involvement
Stage I T1
Stage II T2
Stage III T3
Stage IV A1 T4a
Stage IV A2 T4b One or more nodules plus gross intrahepatic
portal or hepatic
Stage IV B Any N1, any M1
CT, computed tomography; MRI, magnetic resonance imaging
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Resection was performed by the conventional method of
hepatic inflow dissection and selective vascular pedicle ligation
followed by outflow short hepatic vein ligation in a piggyback
fashion. The anterior approach was applied infrequently in our
series. Radiofrequency-assisted parenchyma transection was per-
formed in 30 patients and Kelly crushing technique with intermit-
tent portal triad in 29 patients. Radiofrequency-assisted bloodless
LR has been described previously.14,15 Intraoperative ultrasound
was performed routinely in patients undergoing hepatectomy.
Drains were placed in all cases and remained in place until
postoperative day 3 unless bile drainage or serosanguinous fluid
>500 cc was noted. The number of tumours, maximal tumour
diameter, histological grade based on the modified Edmondson
criteria16 for the degree of tumour differentiation, and the
presence or absence of microvascular invasion were recorded.
Tumours were staged on the basis of pathological evaluation of
the specimen and according to the American Liver Tumor Study
Group (ALTSG) modified tumour–node–metastasis (TNM) clas-
sification17 (Table 1). Vascular invasion included microscopic
involvement of vessels as well as macroscopic invasion; the latter
was defined as the invasion of the branches of the main portal
vein (right or left, not including sectoral branches) or of one or
more of the three hepatic veins (right, middle or left). Multiple
tumours included satellitosis, multifocal tumours and intrahe-
patic metastasis.18 Microscopic margins of resection were con-
sidered positive if there were tumour cells present at the tested
margins (R1).
All patients were followed after surgery and underwent CT
scans of the chest and abdomen every 3 months for the first 2 years
and every 6 months thereafter. In addition, AFP level was mea-
sured every 3 months. Additional imaging techniques (MRI, bone
scintigraphy) were performed if recurrent HCC was suspected.
Recurrence of HCC was categorized according to localization,
either as extrahepatic recurrence or recurrence in the liver only.
Treatment of recurrent HCC included radiofrequency ablation
(RFA), transarterial chemoebolization (TACE) or both, and tar-
geted chemotherapy (sorafenib). Patients with hepatic recurrence
only after LR were considered for repeat hepatectomy or salvage
LT if HCC recurred at an early stage (ALTSG stages I and II).
Statistical analysis
Chi-square test or Fisher’s test, where appropriate, were used
for univariate comparisons. Survival was determined using the
Kaplan–Meier method and comparisons were made with log-rank
statistics. Multivariate logistic regression and the Cox model with
determination of the hazard ratio were applied to evaluate the risk
associated with prognostic variables. Differences were considered
significant at P = 0.05.
Results
Tumour pathology is summarized in Table 2. Median AFP was
760 ng/ml (range 540–1000 ng/ml). A total of 38 patients had a
MELD score <9 and 21 patients presented with MELD scores of
9–11. Microvascular invasion and the mean number of tumour
nodules were significantly greater in patients exceeding UCSF
criteria. The presence of satellitosis and degree of differentiation
were similar in the treatment groups.
Extended hepatectomies were performed more frequently
when patients exceeded UCSF criteria (Table 2).
No perioperative mortality was documented. Morbidity
consisted of biliary fistula, peri-hepatic abscess, pleural effusion
and pneumonia (Table 3). The complication rate was higher in the
group of patients exceeding UCSF criteria.
Median follow-up was 29 months (range 1–60 months) for the
entire cohort, 33 months (range 1–60 months) for patients within
the UCSF criteria (group A) and 27 months (range 1–60 months)
for patients exceeding UCSF criteria (group B). Cumulative 1-,
3- and 5-year disease-free survival rates were 66%, 37% and 34%,
respectively, in group A, significantly higher than in group B,
where 1-, 3- and 5-year disease-free survival rates were 56%, 29%
and 26%, respectively (Table 4). Overall survival rates at 1, 3 and
5 years were 73%, 39% and 35%, respectively, for patients in
group A. Overall survival rates at 1, 3 and 5 years in group B were
significantly lower, at 64%, 35% and 29%, respectively (Table 4).
Death was caused by recurrence and tumour dissemination.
Recurrence was significantly greater in patients who exceeded
UCSF criteria (Table 4). The remnant liver was the most common
site of recurrence. Radiofrequency was the most commonly used
treatment for recurrent HCC, followed by TACE and targeted
chemotherapy (sorafenib). Repeated hepatic resection was not
feasible in this cohort because of low functional reserve and
advanced disease. Some patients were listed for salvage LT but
were not transplanted because of tumour progression during
the waiting time.
The association of various clinicopathological factors with
survival was evaluated. Among the most influential on univariate
analysis were tumour grade, tumour size and number of lesions.
Of little or no influence were age, gender, aetiology of liver disease,
Child classification, MELD score, AFP level, preoperative treat-
ment, microvascular invasion, satellitosis and tumour distri-
bution. On multivariate analysis, only tumour size and grade
remained independent predictors of adverse longterm outcome.
Discussion
Treatment of HCC remains very challenging because a delicate
balance must be maintained between radical tumour excision and
maximal parenchymal preservation. Orthotopic liver transplanta-
tion (OLT) theoretically seems to be superior to resection in
cirrhotic patients because it provides complete tumour excision
and simultaneous treatment of the underlying liver pathology.
The ideal test of the benefit of any treatment is a randomized
prospective trial, but such studies are limited for patients with
HCC.19 The existing treatment strategies have been based on
theoretical analyses and several cohort investigations.20–22 Access
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to treatment options is a serious parameter and must be incorpo-
rated into decision making, given the limited availability of organs
for OLT. In our study, ‘large HCC’ was defined as HCC > 5 cm, and
these ranged from 5 cm to 12 cm.
Despite the theoretical advantage, satisfactory results after OLT
have been confirmed only for patients fulfilling the Milan4 or
UCSF criteria.5 Numerous retrospective studies from the 1990s
have demonstrated that the outcome after OLT for HCCs exceed-
ing UCSF criteria is poor in relative terms, with 5-year survival
rates of <20–30%.23–25
However, acceptable outcomes after resection of HCC exceed-
ing UCSF criteria have been reported by a number of centres. A
multicentre study of 300 patients with HCC > 10 cm reported a
5-year overall survival rate of 26.9%.26 Poon et al. reported a
5-year actual survival rate of 20.6% for 58 patients resected for
tumours > 10 cm.27 Our 5-year survival rate after LR in patients
exceeding UCSF criteria was 29%. We were able to undertake
major or extended resections in patients with HCCs that exceeded
UCSF criteria. In this setting, our preference was to consider only
patients with a MELD score < 9, normal bilirubin and no signs of
ascites or encephalopathy. As we previously reported, in agree-
ment with other reports in the literature, a MELD score > 9 is
associated strongly with higher postoperative morbidity.28,29
Recurrence after resection for large HCC exceeding UCSF
transplantation criteria has been reported to be as high as 82%
within 3 years of resection.11,12,30,31 Higher recurrence rates in large
Table 2 Clinical and pathological characteristics of patients undergoing liver resection for large hepatocellular carcinoma
Liver resection P-value
Fulfilling UCSF criteria Exceeding UCSF criteria
Patients, n 32 27
Mean age, years (range) 63 (49–73) 65 (52–72) 0.1
Aetiology
Hepatitis B 16 (50%) 13 (48%) 0.3
Hepatitis C 10 (31%) 5 (19%)
Other 6 (19%) 9 (33%)
CTP score, mean (range) 5 (5–6) 6 (5–6) 0.2
MELD score, mean (range) 8 (7–14) 9 (8–14) 0.1
Tumour size, cm, mean (range) 6 (2–6.5) 9 (6.5–12) 0.008
Solitary 28 19 0.07
Nodules, n, mean 2 3 0.04
Microvascular invasion, n 20 (62%) 21 (78%) 0.03
Satellitosis, n 10 (31%) 8 (30%) 0.1
Lobectomy, n 23 9 <0.01
Extended hepatectomy (trisectorectomy), n 9 18 0.02
Tumour-free resection margin 1 cm 29 18 0.03
Differentiation
Good, n 19 12
Moderate, n 13 10 0.08
Poor, n 7 5
ALTSG staging
III, n 36 22
IV A1, n 3 3 0.04
IV A2, n 0 2
Median follow-up 33 months 27 months
UCSF, University of California San Francisco; CTP, Child-Turcotte-Pugh; MELD, model for end-stage liver disease; ALTSG, American Liver Tumor
Study Group
Table 3 Complications after liver resection for large hepatocellular
carcinoma
Liver resection P-value
Fulfilling
UCSF
criteria
Exceeding
UCSF
criteria
Patients, n 32 27
Biliary fistula 2 (6.2%) 2 (7.4%) 0.04
Perihepatic abscess 1 (3.1%) 2 (7.4%) 0.004
Pleural effusion 10 (31.2%) 10 (37%) 0.04
Pneumonia 2 (6.2%) 3 (11%) 0.002
UCSF, University of California San Francisco
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tumours have been found to be related to a higher incidence of
satellite lesions and micro- and macrovascular invasion. In our
cohort, the recurrence rate for patients exceeding UCSF criteria
was 73% within 5 years of resection.
Liver transplantation is considered by many authors to be the
treatment of choice for cirrhotic patients fulfilling the Milan
criteria.4 The Milan group showed that 10-year overall survival
surpassed 70% in 300 liver transplants for HCC that fulfilled the
Milan criteria.4 Such good results have been confirmed world-
wide.32,33 Liver resection is not considered as the first treatment
option in this group of patients, but it is the only potentially
curative method when no graft is available within a reasonable
interval of time or when the patient’s access to transplantation
is limited. Resection for such tumours has shown favourable out-
comes regarding 5-year survival (76–87%), but the recurrence rate
was high, reaching 65–70% at 5 years after resection.34,35
In describing their UCSF criteria, Yao et al.5 expanded the
transplantation norm for treating HCC. This group of patients
in whom HCC exceeds Milan criteria represent the most difficult
category of patients regarding the treatment plan. Yao et al.
reported a 5 year survival rate > 70% after transplantation with
the new extended criteria.36 A recent multicentre retrospective
analysis reported that 5-year survival was > 50% after OLT in
patients with extended criteria.35 However, at least three transplant
experiences from Europe and the USA have underlined the
limitations of the applicability of the UCSF criteria in the
pre-transplant setting, particularly as most of the patients who
adhered to the UCSF criteria also fulfilled the Milan criteria.37,38
Although the UCSF criteria have been independently validated in
several studies, the population of patients who adhere to the
UCSF, but not the Milan, criteria is often negligible and estimated
to represent < 10% of the total transplanted population.39,40 Such
a limitation was evidenced by a multicentre study from France, in
which 39 of 461 patients (8.7%) had explanted tumours beyond
the Milan but within the UCSF criteria.37 Although the 5-year
survival rate of 67% for patients meeting UCSF criteria was
equivalent to that of the 183 patients meeting Milan criteria (and
significantly better than the 34% 5-year survival rate of 238
patients exceeding both sets of criteria), the 44 patients meeting
UCSF but exceeding Milan criteria at pre-transplant staging had
a 5-year survival rate of only 48%. This can be compared with
the 60% rate observed in the 272 patients who fulfilled the Milan
criteria and the 37% rate in 121 patients whose symptoms fell
outwith both sets of criteria.
It should be remembered that although transplantation criteria
have been expanded, patients with well-preserved liver function
and with HCC beyond Milan criteria are unlikely to receive a
liver from a deceased individual in a timely manner, given the
current organ allocation system in the USA.41 Using an arbitrary
index rate or snapshot, Shiffman et al.42 showed that only 1.6% of
patients on the liver waiting list with MELD scores of < 11 (like
our cohort of patients in the LR group) underwent LT within 90
days of the snapshot. Only 6% of patients with MELD scores of
11–20 received a liver transplant within 90 days of the snapshot.
With increasing waiting times for OLT, patients with HCC face
the prospect of their disease progressing beyond the limits fixed
by transplant criteria while they wait for a suitable donor. Overall,
5-year survival rate decreases by 10–20% (from 81–58% to
62–47%) for waiting times of 6–12 months, and dropout rates
range from 10% to 30%.6
There are no firm guidelines regarding the optimal treatment
(OLT or LR) for tumours that fall between the Milan and UCSF
criteria. The decision depends not only on the expected out-
come, which seems to favour OLT, but on graft availability and
method applicability as well. Lower 5-year survival and higher
5-year recurrence rates for LR (35% and 70%, respectively)
compared with OLT (53% and 35%, respectively) have been
reported.10,11,23,35 The 5-year disease-free survival and overall
survival rates after LR in patients fulfilling UCSF criteria were
34% and 35%, respectively, in our cohort. Yao et al. reported that
tumour recurrence was 11.4% after OLT in patients who fulfilled
UCSF criteria.5 In the same cohort, Kaplan–Meier survival rates
at 1 and 5 years were 91.3% and 72.4%, respectively, for patients
with pT1 or pT2 HCC, and 82.4% and 74.1%, respectively, for
pT3 tumours.5
Undertaking LR for patients fulfilling UCSF criteria with a long
waiting time allows us to evaluate disease aggressiveness based
on histology and to perform OLT for recurrence. In the medium-
Table 4 Longterm results after resection of large hepatocellular carcinoma
Liver resection P-value
Fulfilling UCSF criteria Exceeding UCSF criteria
Patients, n 32 27
Median follow-up, months 33 27
1-, 3-, 5-year disease-free survival, % 66, 37, 34 56, 29, 26 <0.01
1-, 3-, 5-year survival, % 73, 39, 35 64, 35, 29 0.04
Total recurrence 22/32 (69%) 20/27 (74%) 0.002
Hepatic only 14/32 (44%) 12/27 (44%) 0.004
Extrahepatic 7/32 (22%) 8/27 (30%)
UCSF, University of California San Francisco
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term, overall survival for patients undergoing LR with early-stage
HCC has been shown to be comparable with that of primary OLT
although recurrence is higher in the resected group.
Those patients with poor prognostic criteria, such as evidenced
by macroscopic vascular invasion or poor differentiation, should
be excluded from possible future OLT because of the high likeli-
hood of tumour recurrence. By contrast, resected patients with
solitary well-differentiated tumours without vascular invasion
can be managed by surveillance and offered OLT only if there is
tumour recurrence or hepatic decompensation. Salvage OLT for
HCC relies upon the principle that patients who have tumour
recurrence following LR are still amenable to OLT. Tanaka et al.
found that 8% of patients who underwent LR for HCC within the
Milan criteria had tumour recurrence that exceeded Milan crite-
ria.43 Conversely, only 22% of patients undergoing LR for tumours
outside the Milan criteria developed post-resection recurrence
that fell within the Milan criteria.43 In our group of patients,
salvage transplantation was not performed because of tumour
dissemination. Multivariate analysis identified size of the primary
tumour and degree of differentiation as risk factors for recurrence
in patients exceeding Milan criteria.43 Others have identified the
presence of portal vein invasion in the resected liver specimen as
the most important predictor of tumour recurrence.44 A number
of molecular indices have been examined in attempts to predict
tumour recurrence. A high level of telomerase activity is reported
as an independent predictor for tumour recurrence.45 However,
no marker has been confirmed to predict the risk of tumour
recurrence reliably.
Salvage OLT appears to have higher morbidity and mortality
and an increased incidence of tumour recurrence compared
with primary OLT.46 Of 18 patients who underwent salvage OLT
following LR, at Mount Sinai Hospital in New York, two (11%)
died perioperatively and seven (44%) subsequently developed
tumour recurrence.47 Similarly, in 17 patients who underwent
salvage living donor LT (LDLT), bleeding complications were
more common and the perioperative mortality rate (5.9%) was
significantly higher than after primary OLT.48 By contrast, Bel-
ghiti et al. reported that LR prior to OLT did not significantly
increase the operative difficulty of the procedure.10 Furthermore,
they did not find any difference in disease-free or overall survival
between primary and salvage OLT. Patients who underwent
salvage OLT had a mean 20-month disease-free interval before
listing for OLT.10 The longterm outcomes of these therapies are
awaited.
The most commonly used treatment for recurrent HCC in
our study was RFA with or without TACE. In non-resectable
recurrent HCC these are the most commonly used approaches
to treatment.49,50
Overall and disease-free survival were significantly lower in
patients exceeding UCSF criteria after resection in our study. This
was to be expected because more extended resections were per-
formed. In addition, we know that larger tumours are related to
higher incidences of micro- or macrovascular invasion, a higher
incidence of satellitosis, more advanced tumour grade and more
aggressive tumour behaviour.51
The operative mortality of LR for HCC varies from 0.5% to
21.5% and reflects the incidence of hepatic insufficiency associ-
ated with underlying liver disease.52 We experienced no periop-
erative mortality in either of our two patient groups. In addition,
the rate of ‘recurrent’ disease has been shown to be significantly
higher after LR compared with OLT, with 3-year recurrence-free
survival rates of 83% and 18%, respectively.53 The 3-year disease-
free survival rates after LR were 37% and 29% for patients who
met and those who exceeded the UCSF criteria, respectively, in our
cohort.
It is apparent that in the presence of chronic liver disease, OLT
offers the greatest chance of longterm survival for patients with
small (<5 cm) tumours. Liver resection can be performed for such
tumours when the patient has no access to transplantation, but
he or she must be very closely followed because of the increased
risk of recurrence. Patients with HCC that fall between the Milan
and UCSF criteria seem to have a better outcome after OLT.36 In
the present climate of donor organ scarcity, given that not all
patients can be referred to transplant centres, LR can be consid-
ered as a valuable option in this group of patients. Liver resection,
if feasible, is potentially curative and gives the patient the chance
of instant tumour excision and pathological analysis of the
tumour. These data regarding the tumour may be useful when
salvage transplantation is considered for the treatment of possible
future recurrence. For patients with resectable tumours, which
exceed UCSF criteria, LR, if feasible, is the treatment of choice.
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